Developmental Reserach Pilot Projects

发展研究试点项目

• 批准号: 8932132
• 负责人: WILLIAM A CLIBY
• 金额: $ 9.49万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-01 至 2020-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8932132
• 关键词: Address; Advisory Committees; Award; Cancer Patient; Chicago; Clinic; Clinical Investigator; Clinical Research; Clinical Trials; Collaborations; Communities; Creativeness; Data; Development; Direct Costs; Disabled Persons; Disease; Facilities and Administrative Costs; Fostering; Foundations; Funding; Goals; Grant; Human Resources; Individual; Innovative Therapy; Institution; Intervention; Laboratory Study; Letters; Malignant neoplasm of ovary; Mayo Clinic Cancer Center; Measures; Minnesota; Minority; Monitor; Ovarian; Peer Review; Pharmaceutical Preparations; Pilot Projects; Platinum; Policies; Population; Population Study; Principal Investigator; Process; Publications; Recommendation; Research; Research Personnel; Research Project Grants; Research Support; Resistance; Selection Criteria; Stimulus; System; Testing; Time; TimeLine; Translating; Translational Research; Uncertainty; United States National Institutes of Health; Universities; Woman; Work; Writing; anticancer research; base; cancer research center director; clinically relevant; experience; flavopiridol; improved; innovation; interdisciplinary collaboration; interest; originality; programs; sound; success

ABSTRACT – Developmental Research Program The goal of the Developmental Research Program (DRP) in the Mayo Clinic SPORE in Ovarian Cancer is to support innovative, scientifically sound research projects from which findings can be translated into clinically relevant interventions that will reduce the burden of ovarian cancer. This program was highly successful over the last 5 years, with support going to 30 pilot projects, twelve of which have received additional funding outside of the SPORE based on their pilot project, two that were awarded a second year of funding, one that advanced to a full project within the first funding period, and six that provided data instrumental for the selection of the major research projects in this renewal. This relatively junior program, having received only 58 months of funding at the time of this writing, has 37 associated publications and 10 associated clinical trials. We will build on the success of our first funding period, which attracted investigators new to ovarian cancer research who ultimately became Principal Investigators of projects included in this SPORE application or were awarded NIH funding outside of the SPORE. The DRP will 1) foster innovative laboratory, population, and clinical study proposals that have strong translational potential; 2) encourage and support interdisciplinary collaboration in translational research in ovarian cancer; and 3) generate new hypotheses that can be tested in larger scale research projects or clinical trials in ovarian cancer. The DRP will provide $200,000 annually ($100,000 from the SPORE and a matching $100,000 from Mayo) to support at least four meritorious projects with $50,000 to be used within one year. In the first five years of our SPORE, we generated $990K direct dollars of institutional/Foundation support, approximately double the $500K proposed in the application for this time period; we will continue to seek additional support for ovarian cancer research in the years to come. Depending on the progress of a given project, there will be the possibility of a second year of support after competitive review of both new and continuation projects. The DRP will utilize a defined process to call for applications on an annual basis and to review submissions, utilizing the expertise of the Internal Scientific Advisory Committee and other experienced investigators as needed. Criteria for selection will include: the likelihood that the work will impact major challenges in ovarian cancer, scientific merit, originality, translational potential, qualifications of the key personnel, and interactivity. As experienced in our first funding period, it is anticipated that support of pilot projects through this program will generate new hypotheses that can be addressed in existing SPORE-sponsored projects or through peer-reviewed external grant support.

摘要——发展研究计划 Mayo Clinic SPORE 卵巢癌发展研究计划 (DRP) 的目标是 支持创新、科学合理的研究项目，将研究结果转化为临床 相关干预措施将减轻卵巢癌的负担。 过去 5 年，支持了 30 个试点项目，其中 12 个项目获得了额外资金 在 SPORE 之外，基于他们的试点项目，其中两个获得了第二年的资助，一个是 在第一个资助期内推进到一个完整的项目，其中六个为项目提供了有用的数据 本次更新的主要研究项目的选择这个相对初级的项目，仅收到了58个。 截至撰写本文时，已获得数月的资助，拥有 37 篇相关出版物和 10 项相关临床试验。 我们将在第一个资助期的成功基础上再接再厉，该资助期吸引了卵巢癌领域的新研究人员 最终成为该 SPORE 申请中包含的项目的首席研究员的研究人员或 在 SPORE 之外获得 NIH 资助将 1) 培养创新实验室、人群和 具有强大转化潜力的临床研究提案；2）鼓励和支持跨学科； 卵巢癌转化研究方面的合作；3) 产生可在以下领域进行检验的新假设： DRP 每年将提供 20 万美元的卵巢癌大规模研究项目或临床试验。 （SPORE 提供 100,000 美元，Mayo 提供配套的 100,000 美元）支持至少四个有功绩的项目 一年内使用 50,000 美元 在 SPORE 的前五年里，我们直接产生了 99 万美元。 美元的机构/基金会支持，大约是申请中提议的 50 万美元的两倍 未来几年，我们将继续为卵巢癌研究寻求更多支持。 根据特定项目的进展情况，之后有可能获得第二年的支持 DRP 将利用明确的流程来要求对新项目和延续项目进行竞争性审查。 每年一次的申请并利用内部科学委员会的专业知识审查提交的材料 咨询委员会和其他有需要的经验丰富的调查员的选择标准将包括： 这项工作可能会影响卵巢癌的重大挑战、科学价值、原创性、转化性 正如我们在第一个资助期间所经历的那样，它是潜力、关键人员的资格和互动性。 预计通过该计划对试点项目的支持将产生新的假设 在现有 SPORE 资助的项目中或通过同行评审的外部赠款支持解决。